Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Arecor Therapeutics reported positive results from an early-stage clinical trial showing that its insulin product met its primary and secondary goals.
The trial met the primary endpoint of non-inferiority with respect to glucose lowering action as compared with NovoRapid.
'In addition to meeting this primary endpoint, AT278 (500 U/mL) also demonstrated a significantly accelerated early PK/PD profile compared to NovoRapid (100 U/mL), despite a 5-fold increase in concentration. No safety signals were detected,' the company said.
'These phase I clinical results in diabetes patients are clinically significant, and, as currently there are no concentrated (>200U/mL) rapid acting insulin products on the market, AT278 has the potential to be the first such product available to patients,' it added.